快速清除CT-001在被激活蛋白C诱导的凝血病的小鼠中恢复了血液静止
Derek S Sim1, Cornell R Mallari, Maxine Bauzon
1From the Research Department (D.S.S., C.R.M., T.W.H.), Coagulant Therapeutics Corporation; and Consultant of Coagulant Therapeutics Corporation (M.B.), Berkeley, California.
The journal of trauma and acute care surgery
|June 19, 2023
概括
在临床前模型中,CT-001是一种新型的VIIa因子,有效地逆转了活性蛋白C (APC) 引起的出血. 这种促凝剂显示出治疗APC介导的凝血病的潜力,而不会增加血栓形成的风险.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
背景情况:
- 活性蛋白C (APC) 有助于凝血病和死亡率.
- 抵消APC通路可能会减少出血,但需要考虑以后的血栓形成风险.
- 开发了一种新型的因子VIIa,CT-001,具有增强的活性和快速清除.
研究的目的:
- 为了描述CT-001的N-甘氨酸.
- 评估CT-001在多种物种中的药理动力学和清除.
- 评估CT-001在逆转APC介导的凝血性出血方面的疗效.
主要方法:
- 使用液体染色学质谱学分析了N-甘氨酸.
- 药理动力学在小鼠,老鼠和子中进行了评估.
- 凝血试验和出血模型评估了CT-001在APC诱导的凝血病下的功效和疗效.
主要成果:
- CT-001 显示了脱氧化N-甘氨酸的高占用率.
- 在不同物种中,CT-001的血清除率明显高于野生型FVIIa.
- 在体外,CT-001使凝血参数正常化,并在APC介导的出血模型中显著减少血液损失.
- 疗效独立于特兰胺酸,并没有观察到组合时血栓性增加.
结论:
- 在临床前研究中,CT-001有效地纠正了APC途径介导的凝血病.
- CT-001显示出作为安全有效的血凝剂,可用于治疗与APC相关的出血.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
767
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
767
01:09Coagulation
7.2K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
7.2K
01:16Clot Retraction and Fibrinolysis
6.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.5K
01:05Introduction to Hemostasis
8.4K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
8.4K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
8.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.4K
01:29Venous Thrombosis III: Interprofessional Care
11
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
11